A decades-old epilepsy pill may be about to change how doctors treat the achy, grinding knees and hips that come with osteoarthritis.
Quick Take
- Yale researchers found that lacosamide, an FDA-approved epilepsy drug, eased pain and slowed cartilage breakdown in preclinical osteoarthritis models.
- A collagen-II hydrogel delivered the drug straight into the joint, working better than swallowing it as a pill.
- One hydrogel injection every four weeks outperformed a daily oral dose in protecting cartilage.
- The drug targets a pain-and-damage protein called the Nav1.7 sodium channel, found in both nerve cells and cartilage cells.
An Old Drug Finds a Surprising New Job
Lacosamide has treated seizures for about 20 years. Now Yale scientists say it does something nobody expected. Published in the journal Bioactive Materials, their study found the drug reduced joint pain and helped reverse cartilage damage in osteoarthritis models. Researchers call it a disease-modifying candidate, a rare label in a field where most treatments only mask pain instead of fixing the underlying damage.
Osteoarthritis affects millions of older Americans, wearing down the cushion of cartilage between bones until joints grind bone on bone. Current treatments mostly manage pain with injections, anti-inflammatories, or eventually surgery. None of them repair the cartilage itself. That gap is why a drug that might actually rebuild joint tissue, not just numb it, grabbed attention from researchers and patients alike.
Why Delivery Location Matters So Much
The real breakthrough may not be the drug itself but how it gets to the joint. Yale’s team built a hydrogel using collagen II, a protein naturally found in cartilage, to carry lacosamide directly into the damaged area. Dr. Yale’s own orthopaedic team describes targeting the Nav1.7 sodium channel and delivering the drug locally as something that goes beyond reducing pain. The gel keeps the medicine in place longer instead of flushing through the whole body.
That local approach beat the traditional pill-swallowing method in head-to-head testing. One hydrogel injection every four weeks outperformed a daily oral dose at preventing cartilage loss, according to the study. Intra-articular, or in-joint, administration achieved stronger protection and pain relief at one-tenth the dose needed systemically. Lower doses delivered right where they’re needed could mean fewer side effects for patients down the road.
The Science Behind the Protein Target
Researchers zeroed in on Nav1.7, a sodium channel protein already known for its role in pain signaling. It turns out the same protein also plays a part in cartilage destruction. By blocking it, lacosamide appears to do double duty: dulling pain signals while also slowing the breakdown process that destroys joint tissue over time. At the right low concentration, the drug boosted production of proteins tied to cartilage building and suppressed the tissue-destroying process, though the effect weakened at concentrations too high or too low.
This dual mechanism is what separates the Yale findings from typical arthritis treatments. Most existing options, like over-the-counter pain relievers or steroid shots, only address discomfort. None of them are proven to rebuild what’s already broken down. If lacosamide truly nudges damaged cartilage toward repair rather than just slowing further decay, that would mark a meaningful shift in how the disease gets managed.
Setting Expectations for What Comes Next
These results come from preclinical studies, meaning they were tested in lab and animal models, not yet in large human trials. That’s standard early-stage science, and it’s worth remembering that promising animal findings don’t always carry over to people. Still, the fact that lacosamide is already FDA-approved for epilepsy could speed up any future path toward testing it for osteoarthritis in humans, since its safety profile is already well understood.
For the roughly one in seven American adults living with osteoarthritis, repurposing an existing, well-tested drug offers a faster and cheaper route than inventing something new from scratch. Yale’s own orthopaedic experts note that laboratory work increasingly suggests some of the biological pathways driving cartilage damage can be interrupted, and under the right conditions, repair may even be stimulated. That’s a cautiously optimistic message, grounded in real data rather than hype, and conservative readers skeptical of overblown medical promises should appreciate that the researchers are staying grounded in what the evidence actually shows.
FDA-approved epilepsy drug lacosamide shows potential to help reverse osteoarthritis damage. Yale researchers found it may block a protein involved in pain signaling and cartilage destruction, nudging damaged joints toward repair in preclinical studies. https://t.co/wFvuzgVMDo pic.twitter.com/A0PgUBXlWb
— Drew Grimaldi (@Grimillionaire) October 8, 2026
Osteoarthritis has long been treated as an inevitable part of aging, something to manage rather than fix. If further research confirms what Yale’s preclinical work suggests, that assumption may not hold much longer. For now, the findings offer a genuinely hopeful data point in a field that hasn’t had many.
Sources:
medicine.yale.edu, sciencedaily.com, ua.news, inc.com
